Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04340388 · ClinicalTrials.gov registry record · Phase 4
Contribution of Dolutegravir to Obesity and Cardiovascular Disease
A Phase 4 study, sponsored by Augusta University.
- Completed
- Registry status
- Phase 4
- Development phase
- 10
- Enrollment target
NCT04340388 is a Phase 4 study that has completed, run by Augusta University. The registered enrollment target is 10 participants.
The verdict
NCT04340388, a Phase 4 study, has completed, sponsored by Augusta University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 10 participants
- Enrollment target
Study Summary
The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir based regimen on on lipid and metabolic profiles, renal function, body composition, vascular function and diet.
Interventions
- DRUG Dolutegravir 50 MG
- DRUG Antiretroviral/Anti HIV
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-09-17 |
| Est. Completion | 2023-02-25 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04340388
The ClinicalTrials.gov registry entry for NCT04340388 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Augusta University, which has 106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dolutegravir 50 MG is the first listed.
NCT04340388 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04340388 about?
NCT04340388 is a clinical study titled "Contribution of Dolutegravir to Obesity and Cardiovascular Disease". The goal of the study is to combine a collaborative and translational approach to evaluate the effect antiretroviral regimen switch to a dolutegravir containing regimen compared to continued treatment with a non- dolutegravir based regimen on on lipid and metabolic profiles, renal function, body com...
What is the current status of trial NCT04340388?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2020-09-17. Estimated completion is 2023-02-25.
What interventions are being tested in trial NCT04340388?
The interventions under investigation include: Dolutegravir 50 MG (DRUG), Antiretroviral/Anti HIV (DRUG).
Who is sponsoring clinical trial NCT04340388?
This trial is sponsored by Augusta University, which has 106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.